Journal of clinical medicine . 2022 Sep 22;11(19):5575. doi: 10.3390/jcm11195575. Philippe Rigoard, Amine Ounajim, Lisa Goudman, Chantal Wood, Manuel Roulaud, Philippe Page, Bertille Lorgeoux, Sandrine Baron, Kevin Nivole, Mathilde Many, Emmanuel Cuny, Jimmy Voirin, Denys Fontaine, Sylvie Raoul, Patrick Mertens, Philippe Peruzzi, François Caire, Nadia Buisset, Romain David, Maarten Moens, Maxime Billot Abstract Spinal cord stimulation (SCS) is an effective
Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data
Cephalalgia 2022 Sep 8;3331024221123058. doi: 10.1177/03331024221123058. Online ahead of print. Michel Lanteri-Minet, Anne Ducros , Clement Francois, Elzbieta Olewinska, Mateusz Nikodem, Laure Dupont-Benjamin Abstract Background: This meta-analysis evaluated the real-world effectiveness of onabotulinumtoxinA (BOTOX®), the first preventive treatment FDA-approved specifically for chronic migraine in 2010.
Treatment of Chronic Refractory Pain by Combined Deep Brain Stimulation of the Anterior Cingulum and Sensory Thalamus (EMOPAIN Study): Rationale and Protocol of a Feasibility and Safety Study
Brain sciences 2022 Aug 23;12(9):1116. Aurélie Leplus, Michel Lanteri-Minet, Anne Donnet, Nelly Darmon, Jean Regis, Denys Fontaine Abstract Background: Deep Brain Stimulation (DBS) of the sensory thalamus has been proposed for 40 years to treat medically refractory neuropathic pain, but its efficacy remains partial and
Antibody-induced pain-like behavior and bone erosion: links to subclinical inflammation, osteoclast activity, and acid-sensing ion channel 3-dependent sensitization
Pain 2022 Aug 1;163(8):1542-1559.doi: 10.1097/j.pain.0000000000002543. Epub 2021 Nov 19. Alexandra Jurczak, Lauriane Delay, Julie Barbier, Nils Simon, Emerson Krock, Katalin Sandor , Nilesh M Agalave, Resti Rudjito, Gustaf Wigerblad, Katarzyna Rogóż, Arnaud Briat, Elisabeth Miot-Noirault, Arisai Martinez-Martinez, Dieter Brömme, Caroline Grönwall, Vivianne Malmström, Lars Klareskog, Spiro Khoury, Thierry Ferreira, Bonnie Labrum, Emmanuel Deval, Juan Miguel Jiménez-Andrade, Fabien Marchand, Camilla I Svensson Erratum in
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial
The Lancet Neurology 2022 Jul;21(7):597-607 doi: 10.1016/S1474-4422(22)00185-5. Messoud Ashina, Michel Lanteri-Minet, Patricia Pozo-Rosich, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling Abstract Background: The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and
Single Subcutaneous Injection of Lysophosphatidyl-Choline Evokes ASIC3-Dependent Increases of Spinal Dorsal Horn Neuron Activity
Frontiers in molecular neuroscience 2022 Jun 14;15:880651 doi: 10.3389/fnmol.2022.880651. eCollection 2022. Ludivine Pidoux, Kevin Delanoe, Julie Barbier, Fabien Marchand, Eric Lingueglia, Emmanuel Deval Abstract Lysophosphatidyl-choline (LPC), a member of the phospholipid family, is an emerging player in pain. It is known to modulate different pain-related
Occipital Nerve Stimulation for Recurrent Trigeminal Neuralgia Without Occipital Pain
Neuromodulation : Journal of the International Neuromodulation Society 2022 Jun 7;S1094-7159(22)00649-3. doi: 10.1016/j.neurom.2022.03.012. Online ahead of print. Anne Balossier, Anne Donnet, Jean Régis, Aurélie Leplus , Michel Lantéri-Minet, Denys Fontaine Abstract Objectives: Trigeminal neuralgia (TN) is a severe, debilitating pain condition causing physical and emotional
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database
The journal of headache and pain 2022 May 3;23(1):53 doi: 10.1186/s10194-022-01424-w. Alexandre O Gérard, Diane Merino, Elise K Van Obberghen, Fanny Rocher, Alexandre Destere, Michel Lantéri-Minet, Milou-Daniel Drici Abstract Background: Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide
Practice guidelines for the treatment of acute migraine and chronic knee osteoarthritis with paracetamol: an expert appraisal on evolution over time between scientific societies
Current Medical Research and Opinion 2022 May 13;1-18 doi: 10.1080/03007995.2022.2076475. Online ahead of print. Serge Perrot, Alain Eschalier, Jules Desmeules, Michel Lanteri-Minet, Nadine Attal Abstract Background: Paracetamol is the commonest analgesic worldwide in primary care. Despite evidence-based recommendations for management of acute and chronic
Artificial intelligence to evaluate postoperative pain based on facial expression recognition
European Journal of Pain 2022 Mar 30 doi: 10.1002/ejp.1948. Online ahead of print. Denys Fontaine, Valentin Vielzeuf, Philippe Genestier, Pascal Limeux, Serena Santucci-Sivilotto, Emmanuel Mory, Nelly Darmon, Michel Lanteri-Minet, May Mokhtar, Melanie Laine, Damien Vistoli, DEFI study group Abstract Background: Pain intensity evaluation by self-report is difficult and biased in